CN103536529A - 含头孢噻呋长效注射剂及制备方法 - Google Patents
含头孢噻呋长效注射剂及制备方法 Download PDFInfo
- Publication number
- CN103536529A CN103536529A CN201310521707.2A CN201310521707A CN103536529A CN 103536529 A CN103536529 A CN 103536529A CN 201310521707 A CN201310521707 A CN 201310521707A CN 103536529 A CN103536529 A CN 103536529A
- Authority
- CN
- China
- Prior art keywords
- preparation
- ceftiofur
- injection
- saib
- ethyl oleate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 50
- 239000007924 injection Substances 0.000 title claims abstract description 50
- 229960005229 ceftiofur Drugs 0.000 title claims description 15
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title abstract description 94
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 claims abstract description 56
- KEQFDTJEEQKVLM-JUODUXDSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydron;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 KEQFDTJEEQKVLM-JUODUXDSSA-N 0.000 claims abstract description 29
- 229960001356 ceftiofur hydrochloride Drugs 0.000 claims abstract description 29
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract description 26
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract description 26
- 229940093471 ethyl oleate Drugs 0.000 claims abstract description 26
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims abstract description 23
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims abstract description 23
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960002903 benzyl benzoate Drugs 0.000 claims abstract description 12
- 239000004359 castor oil Substances 0.000 claims abstract description 3
- 235000019438 castor oil Nutrition 0.000 claims abstract description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 3
- 229940074928 isopropyl myristate Drugs 0.000 claims abstract 2
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 claims description 14
- 229960004467 ceftiofur sodium Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- QSHVAZMOLNGWSY-UHFFFAOYSA-N 3-butyl-4-methoxyphenol Chemical group CCCCC1=CC(O)=CC=C1OC QSHVAZMOLNGWSY-UHFFFAOYSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- -1 Benzyl Benzoate ester Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 abstract 2
- 239000001797 sucrose acetate isobutyrate Substances 0.000 abstract 2
- 229940063655 aluminum stearate Drugs 0.000 abstract 1
- 239000002612 dispersion medium Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000004576 sand Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 description 7
- 239000008158 vegetable oil Substances 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310521707.2A CN103536529A (zh) | 2013-10-30 | 2013-10-30 | 含头孢噻呋长效注射剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310521707.2A CN103536529A (zh) | 2013-10-30 | 2013-10-30 | 含头孢噻呋长效注射剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103536529A true CN103536529A (zh) | 2014-01-29 |
Family
ID=49960647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310521707.2A Pending CN103536529A (zh) | 2013-10-30 | 2013-10-30 | 含头孢噻呋长效注射剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103536529A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352501A (zh) * | 2014-11-10 | 2015-02-18 | 重庆泰通动物药业有限公司 | 一种复方头孢噻呋钠注射剂 |
CN106176598A (zh) * | 2016-08-30 | 2016-12-07 | 林州中农颖泰生物肽有限公司 | 一种盐酸头孢噻呋混悬注射液及其制备方法 |
-
2013
- 2013-10-30 CN CN201310521707.2A patent/CN103536529A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352501A (zh) * | 2014-11-10 | 2015-02-18 | 重庆泰通动物药业有限公司 | 一种复方头孢噻呋钠注射剂 |
CN106176598A (zh) * | 2016-08-30 | 2016-12-07 | 林州中农颖泰生物肽有限公司 | 一种盐酸头孢噻呋混悬注射液及其制备方法 |
CN106176598B (zh) * | 2016-08-30 | 2019-01-08 | 林州中农颖泰生物肽有限公司 | 一种盐酸头孢噻呋混悬注射液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3292860B1 (en) | Cabazitaxel fat emulsion injection, and preparation method and use thereof | |
JPH11514650A (ja) | 治療用シスプラチン(cddp)のための改良された方法及び組成物 | |
CN102038635A (zh) | 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法 | |
CN103536530A (zh) | 盐酸多西环素长效注射剂及制备方法 | |
CN103550149A (zh) | 含抗寄生虫药物长效注射剂的制备技术 | |
CN103536529A (zh) | 含头孢噻呋长效注射剂及制备方法 | |
CN103550150B (zh) | 改进的含二甲基硅油的注射剂 | |
CN102481287B (zh) | 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法 | |
CN103520098A (zh) | 恩诺沙星兽用长效注射剂的制备方法 | |
CN103520099A (zh) | 含有效成份为沃尼妙林的长效注射剂 | |
CN103550151A (zh) | 硫酸头孢喹诺长效注射剂制备方法 | |
CN103550152A (zh) | 替米考星兽用长效注射剂制备方法 | |
CN103550148A (zh) | 延胡索酸泰妙菌素长效注射剂制备方法 | |
CN103536531A (zh) | 甲磺酸达氟沙星长效注射剂制备方法 | |
CN102188370B (zh) | 一种白藜芦醇注射溶液及其静脉注射剂 | |
CN103550221A (zh) | 含延胡索酸泰妙菌素和硫酸头孢喹诺的复方注射剂 | |
CN103520168A (zh) | 含延胡索酸泰妙菌素的复方注射剂 | |
CN101883563B (zh) | 含多烯紫杉醇化合物的注射剂及其配制方法 | |
CN103550220A (zh) | 含盐酸恩诺沙星和盐酸头孢噻呋的长效注射剂 | |
CN103520166A (zh) | 含甲磺酸达氟沙星和头孢噻呋的长效注射剂 | |
CN103520167A (zh) | 含硫酸头孢喹诺和甲磺酸达氟沙星的长效注射剂 | |
CN103550228A (zh) | 含盐酸头孢噻呋与盐酸多西环素的复方注射剂 | |
JP6189437B2 (ja) | 注射用抗生物質製剤およびその使用方法 | |
US10064883B2 (en) | Lipiodol-based anti-tumour emulsion for treating cancer | |
CN103520189A (zh) | 含硫酸头孢喹诺与盐酸多西环素的复方注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YOU XIHUO Effective date: 20150112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150112 Address after: 102206 Beijing city Changping District Baishan Town East Village profile West Industrial Zone No. 535 Pro Applicant after: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Address before: 102206 Beijing city Changping District Baishan Town East Village profile West Industrial Zone No. 535 Pro Applicant before: You Xihuo |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140129 |